- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00113698
Angiotensin Converting Enzyme Inhibition in Children With Mitral Regurgitation (AceiMR)
Trial of ACE Inhibition in Children With Mitral Regurgitation After Repair of AVSD
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
BACKGROUND:
MR causes volume overload and hemodynamic burden on the left ventricle. Initial compensatory mechanisms may fail, leading to increased severity. Patients who have had repair of an atrioventricular septal defect (AVSD) are selected for this study as they have a relatively high incidence of moderate MR and their regurgitant orifice is mobile and dynamic, contributing to the likelihood that they might respond to medical therapy.
DESIGN NARRATIVE:
This is a randomized, double-blind, placebo-controlled trial of ACE-I therapy in children less than 18 years of age with at least moderate MR who are at least 6 months postoperative from repair of an AVSD. A non-randomized Observational Phase enrolled 181 children who were less than 6 months postoperative from repair of an AVSD, who were then evaluated at 6 months for trial eligibility.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X8
- Hospital for Sick Children
-
-
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02115
- Children's Hospital Boston
-
-
New York
-
New York, New York, Forenede Stater, 10032
- Columbia College of Physicians and Surgeons
-
-
North Carolina
-
Durham, North Carolina, Forenede Stater, 27710
- Duke University Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- Children's Hospital of Philadelphia
-
-
South Carolina
-
Charleston, South Carolina, Forenede Stater, 29425
- Medical University of South Carolina
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84132
- Primary Children's Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Children less than 18 years of age and at least 6 months post AVSD repair or reoperation
- At least moderate MR
- Asymptomatic or minimally symptomatic, defined by Ross Heart Failure Class I or II
- Atrioventricular synchrony (paced or intrinsic)
Exclusion Criteria:
- Tetrology of Fallot, total or partial anomalous venous connection
- More than trivial MS or outflow obstruction
- Other sources of LV volume overload
- Hypertrophic obstructive cardiomyopathy
- Significant residual coarctation
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Placebo komparator: 1
|
Placebo An inert preparation with similar appearance and taste to the drug
|
|
Aktiv komparator: 2
Ace inhibition (enalapril)
|
Up-titration period is to reach the highest tolerated dose up to a maximum of 0.4 mg/kg/day
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Comparison of the effect of ACE-I therapy with that of placebo on left ventricular size
Tidsramme: Measured after six months of therapy
|
Measured after six months of therapy
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Comparison of the effect of ACE-I therapy with placebo on MR severity, left ventricular geometry, hemodynamics, and signs and symptoms of congestive heart failure
Tidsramme: 6 months on study drug
|
6 months on study drug
|
|
Evaluation of the early natural history of MR in the six months after repair of an AVSD
Tidsramme: 6 months on study drug
|
6 months on study drug
|
|
Comparison of the incidence of adverse events occurring in subjects treated with ACE-I therapy to that in subjects receiving placebo (measured after six months of therapy)
Tidsramme: 6 months on safety drug
|
6 months on safety drug
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: LuAnn Minich, MD, Primary Children's Hospital, Salt Lake City, UT
Publikationer og nyttige links
Generelle publikationer
- Li JS, Colan SD, Sleeper LA, Newburger JW, Pemberton VL, Atz AM, Cohen MS, Golding F, Klein GL, Lacro RV, Radojewski E, Richmond ME, Minich LL. Lessons learned from a pediatric clinical trial: the Pediatric Heart Network angiotensin-converting enzyme inhibition in mitral regurgitation study. Am Heart J. 2011 Feb;161(2):233-40. doi: 10.1016/j.ahj.2010.10.030.
- Atz AM, Hawkins JA, Lu M, Cohen MS, Colan SD, Jaggers J, Lacro RV, McCrindle BW, Margossian R, Mosca RS, Sleeper LA, Minich LL; Pediatric Heart Network Investigators. Surgical management of complete atrioventricular septal defect: associations with surgical technique, age, and trisomy 21. J Thorac Cardiovasc Surg. 2011 Jun;141(6):1371-9. doi: 10.1016/j.jtcvs.2010.08.093. Epub 2010 Dec 15.
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Hjertesygdomme
- Hjerte-kar-sygdomme
- Hjerteklapsygdomme
- Kardiovaskulære abnormiteter
- Hjertefejl
- Mitralventilinsufficiens
- Medfødte abnormiteter
- Hjerteseptumdefekter
- Hjertefejl, medfødt
- Hjerteseptumdefekter, Ventrikulær
- Molekylære mekanismer for farmakologisk virkning
- Antihypertensive midler
- Enzymhæmmere
- Proteasehæmmere
- Angiotensin-konverterende enzymhæmmere
- Enalapril
Andre undersøgelses-id-numre
- 185
- U01HL068292 (U.S. NIH-bevilling/kontrakt)
- U01HL068290 (U.S. NIH-bevilling/kontrakt)
- U01HL068288 (U.S. NIH-bevilling/kontrakt)
- U01HL068285 (U.S. NIH-bevilling/kontrakt)
- U01HL068281 (U.S. NIH-bevilling/kontrakt)
- U01HL068279 (U.S. NIH-bevilling/kontrakt)
- U01HL068270 (U.S. NIH-bevilling/kontrakt)
- U01HL068269 (U.S. NIH-bevilling/kontrakt)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .